Eric W. Thomas

Array ( [id] => 10305502 [patent_doc_number] => 20150190501 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-09 [patent_title] => 'METHODS AND COMPOSITIONS FOR RAISING AN IMMUNE RESPONSE TO HIV' [patent_app_type] => utility [patent_app_number] => 14/344088 [patent_app_country] => US [patent_app_date] => 2012-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 83 [patent_figures_cnt] => 83 [patent_no_of_words] => 23327 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14344088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10945844 [patent_doc_number] => 20140348865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-27 [patent_title] => 'IMMUNOGENS BASED ON AN HIV-1 V1V2 SITE-OF-VULNERABILITY' [patent_app_type] => utility [patent_app_number] => 14/344589 [patent_app_country] => US [patent_app_date] => 2012-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 83 [patent_figures_cnt] => 83 [patent_no_of_words] => 52903 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14344589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9812055 [patent_doc_number] => 20150024001 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-22 [patent_title] => 'MOLECULAR MIMIC MUCOSAL AIDS VACCINE' [patent_app_type] => utility [patent_app_number] => 14/238617 [patent_app_country] => US [patent_app_date] => 2012-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 4774 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14238617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9656307 [patent_doc_number] => 20140227311 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-14 [patent_title] => 'Method for Removing Immunosuppressive Properties of HIV Envelope Glycoproteins' [patent_app_type] => utility [patent_app_number] => 14/239961 [patent_app_country] => US [patent_app_date] => 2012-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 14825 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14239961 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8566075 [patent_doc_number] => 20120328641 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-27 [patent_title] => 'CONFORMATIONALLY STABILIZED HIV ENVELOPE IMMUNOGENS' [patent_app_type] => utility [patent_app_number] => 13/585700 [patent_app_country] => US [patent_app_date] => 2012-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 114341 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13585700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8489094 [patent_doc_number] => 20120288502 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-15 [patent_title] => 'COMPOSITIONS AND METHODS FOR IMPROVING POTENCY AND BREADTH OF HIV ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/558312 [patent_app_country] => US [patent_app_date] => 2012-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 15685 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13558312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8476721 [patent_doc_number] => 20120276128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'HIV Envelope-CD4 Complexes and Hybrids' [patent_app_type] => utility [patent_app_number] => 13/544063 [patent_app_country] => US [patent_app_date] => 2012-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 23496 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13544063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13037413 [patent_doc_number] => 10040826 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-07 [patent_title] => Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens [patent_app_type] => utility [patent_app_number] => 14/130338 [patent_app_country] => US [patent_app_date] => 2012-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 33 [patent_no_of_words] => 14057 [patent_no_of_claims] => 67 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14130338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14261323 [patent_doc_number] => 10280213 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-07 [patent_title] => Broadly cross-reactive HIV-1 Env-specific antibodies [patent_app_type] => utility [patent_app_number] => 13/534834 [patent_app_country] => US [patent_app_date] => 2012-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8334 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 226 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13534834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9448956 [patent_doc_number] => 20140120125 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-01 [patent_title] => 'VACCINE COMPOSITION COMPRISING AN INACTIVATED CHIKUNGUNYA VIRUS STRAIN' [patent_app_type] => utility [patent_app_number] => 14/126504 [patent_app_country] => US [patent_app_date] => 2012-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 8394 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14126504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8495483 [patent_doc_number] => 20120294891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-22 [patent_title] => 'MATERIALS AND METHODS FOR DETECTING, PREVENTING, AND TREATING RETROVIRAL INFECTION' [patent_app_type] => utility [patent_app_number] => 13/476835 [patent_app_country] => US [patent_app_date] => 2012-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 14290 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13476835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8767099 [patent_doc_number] => 20130095136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-18 [patent_title] => 'Tetravalent Dengue Vaccines' [patent_app_type] => utility [patent_app_number] => 13/475202 [patent_app_country] => US [patent_app_date] => 2012-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 32807 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13475202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8405468 [patent_doc_number] => 20120237527 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-20 [patent_title] => 'Polynucleotide Fragments of an Infectious Human Endogenous Retrovirus' [patent_app_type] => utility [patent_app_number] => 13/451256 [patent_app_country] => US [patent_app_date] => 2012-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 13993 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13451256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8482880 [patent_doc_number] => 20120282287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-08 [patent_title] => 'Novel Flavivirus Antigens' [patent_app_type] => utility [patent_app_number] => 13/448099 [patent_app_country] => US [patent_app_date] => 2012-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 126452 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13448099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10919243 [patent_doc_number] => 20140322262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-30 [patent_title] => 'METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS' [patent_app_type] => utility [patent_app_number] => 14/110490 [patent_app_country] => US [patent_app_date] => 2012-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 13494 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14110490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9785268 [patent_doc_number] => 20140302089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-09 [patent_title] => 'PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND/OR TREATING AN HIV DISEASE IN HUMANS' [patent_app_type] => utility [patent_app_number] => 14/009250 [patent_app_country] => US [patent_app_date] => 2012-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 20036 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14009250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13297303 [patent_doc_number] => 20180200188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => Protease Cleavage Site Peptides as an HIV Vaccine [patent_app_type] => utility [patent_app_number] => 14/112622 [patent_app_country] => US [patent_app_date] => 2012-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14112622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9330153 [patent_doc_number] => 20140056935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'PEPTIDE WHICH CAN INDUCE ANTIBODY CAPABLE OF RECOGNIZING STEREOSTRUCTURE OF HIV' [patent_app_type] => utility [patent_app_number] => 14/009757 [patent_app_country] => US [patent_app_date] => 2012-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14251 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14009757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8548782 [patent_doc_number] => 08323662 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2012-12-04 [patent_title] => 'Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein' [patent_app_type] => utility [patent_app_number] => 13/436472 [patent_app_country] => US [patent_app_date] => 2012-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 13 [patent_no_of_words] => 27809 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13436472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14246199 [patent_doc_number] => 10273291 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-30 [patent_title] => Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing [patent_app_type] => utility [patent_app_number] => 14/116710 [patent_app_country] => US [patent_app_date] => 2012-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 146 [patent_figures_cnt] => 121 [patent_no_of_words] => 22224 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14116710 [rel_patent_id] =>[rel_patent_doc_number] =>)